Anthos Logo Transparent.png
Regulatory Authorities in China and Japan Approve Clinical Trials for Anthos Therapeutics’ Dual-Acting Factor XI/XIa Inhibitor Abelacimab
08 juin 2023 11h10 HE | Anthos Therapeutics
Fewer than 26% of Chinese Patients with Atrial Fibrillation are Prescribed an Anticoagulant, while in Japan Almost One-Third of Patients are Undertreated Approximately 63% of Cancer Patients in China...
Anthos Logo Transparent.png
New Assessment Scale to Measure Adherence to Oral Anticoagulants Based on Impact of Patient Relevant Bleeding in Atrial Fibrillation Presented at ISPOR 2023
09 mai 2023 09h45 HE | Anthos Therapeutics
Anticoagulant Bleeding Burden Adherence Confidence Assessment Scale [ABBA-CAS] Created to Better Address an Important Treatment Gap in the Management of Atrial Fibrillation (AF) and Bring Patient...
Anthos Logo Transparent.png
New Assessment Scale to Capture Patient Relevant Bleeding to be Presented at ISPOR 2023
05 mai 2023 08h00 HE | Anthos Therapeutics
Additional presentation spotlights GARDENIA registry design in patientswith atrial fibrillation and atrial flutter Early Cost-Effectiveness Modeling for Patients with Atrial Fibrillation and Cancer...
Atrial Fibrillation Market Worth $20.92 Billion, Globally, by 2028 at 14.11% CAGR | The Insight Partners
04 avr. 2023 09h45 HE | The Insight Partners
Pune, INDIA., April 04, 2023 (GLOBE NEWSWIRE) -- According to our latest study on "Atrial Fibrillation Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Treatment Type, End User,...
MicrosoftTeams-image (5).png
Cardiotonic Agents Market Size to Reach USD 4.5 Bn by 2031 Due to the Rise in Prevalence of Cardiovascular Diseases | TMR Study
03 avr. 2023 11h30 HE | Transparency Market Research
Wilmington, Delaware, United States, April 03, 2023 (GLOBE NEWSWIRE) -- According to the market study by Transparency Market Research, the global cardiotonic agents market was worth USD 732 Million...
Vantage Market Research.png
Atrial Fibrillation Market Size & Share to Surpass $38.9 Billion by 2028 | Vantage Market Research
27 mars 2023 09h27 HE | Vantage Market Research
WASHINGTON, March 27, 2023 (GLOBE NEWSWIRE) -- The global Atrial Fibrillation Market was valued at USD 17.5 Billion in 2022 and is projected to reach a value of USD 38.9 Billion by 2030 at a CAGR...
logo 600X600.png
Global Heparin Calcium Market to Surpass US$ 1,700.8 Million by 2030, Says Coherent Market Insights (CMI)
15 févr. 2023 09h15 HE | CMI
Burlingame, Feb. 15, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global heparin calcium market is estimated to be valued at US$ 1,370.9 in 2022 and is expected to exhibit a...
Holter ECG Market Size Report ($1.21 Billion by 2028) Driven by Rising Prevalence of CVDs – Exclusive Report by The Insight Partners
06 févr. 2023 08h36 HE | The Insight Partners
New York, Feb. 06, 2023 (GLOBE NEWSWIRE) -- According to The Insight Partners, “Holter ECG Market Size, Share, Growth, Trends and Global Forecast to 2028 - COVID-19 Impact and Global Analysis by...
Global Atrial Fibrillation Market Report 2022 to 2028: Increasing Prevalence of Obesity and Cardiac Disorders Drives Growth
19 janv. 2023 04h03 HE | Research and Markets
Dublin, Jan. 19, 2023 (GLOBE NEWSWIRE) -- The "Global Atrial Fibrillation Market Size, Share & Industry Trends Analysis Report by End-user, Type, Technology, Regional Outlook and Forecast,...
Anthos Logo Transparent.png
First Patient Enrolled in Phase 3 Trial Evaluating Abelacimab in High-Risk Patients with Atrial Fibrillation Deemed Unsuitable for Current Anticoagulants
03 janv. 2023 08h00 HE | Anthos Therapeutics
FDA Fast-Track designation was granted to investigate abelacimab for the prevention of stroke and systemic embolism in patients with atrial fibrillation LILAC-TIMI 76 trial is the third Phase 3...